Objectives (1) To identify the cost-driving factors of health expenditure in inflammatory bowel disease (IBD), (2) to determine the effect of different cost-sharing levels on outpatient visits and (3) to determine the effect of different cost-sharing levels on medication adherence among patients with IBD. Method This was a retrospective, longitudinal study in which data were collected from 1999 to 2013 using the Medical Expenditure Panel Survey. The study sample included all patients who had IBD, were at least 18 years old, and had insurance. A comprehensive list of demographic factors was assessed to identify cost-driving factors associated with high level of expenditure in IBD. Two logistic regression models were built to examine the association between outpatient cost sharing and number of outpatient visits, and between prescription cost sharing and medication adherence. Statistical significance was evaluated at P < 0.05. Key findings Significant cost-driving factors included age, body mass index, education, income, quality of life, Charlson Comorbidity Index and region. The study found that low outpatient cost sharing was associated significantly with high level of outpatient visits. However, different levels of prescription cost sharing had no significant relationship with medication adherence. Conclusions The finding confirms the existence of financial barriers to care in IBD, which may lead to suboptimal outpatient and, thus, the rapid worsening of the diseases. The finding of cost-driving factors allows the identification of high-risk group for high expenditure, which can be used for future cost-saving strategy.
Introduction
Inflammatory bowel disease (IBD) is a group of chronic diseases characterized by the inflammation of the gastrointestinal lining tissues. [1] IBD contains two major diseases, ulcerative colitis (UC) and Crohn's disease (CD). [1] While both CD and UC are inflammatory diseases, both have different characteristics in term of location and types of inflamed tissues. [2, 3] IBD has a disease course of alternating periods of flaring and remission. [2, 3] Flaring period is when the clinical signs and symptoms occur, while the remission period is marked with the inactivity of the disease. Patients with either UC or CD can experience symptoms of diarrhoea, abdominal pain, weight loss, fever and/or bloody stool. [2, 3] Complications can include haemorrhage, perforation, malnutrition, abdominal obstruction and extra-intestinal inflammation. [2, 3] Therefore, the therapeutic goal for IBD is to induce and maintain remission, improve quality of life and promote tissue healing. [2] [3] [4] The prevalence for IBD has been increasing in recent years, about 1.2-1.6 million affected patients. [1] The annual direct expenditure for IBD is about $6.7 billion, making the annual cost per patient about $10 000 for CD and $7500 for UC. [5] [6] [7] Additionally, the indirect IBD cost (employee absenteeism) were estimated to be about $249 million in United States (2006's value). [8] Previous studies have identified several factors that associated with higher expenditure in IBD. These factors include age, insurance status, income, body mass index (BMI), gender, race, smoking status and education. [5] [6] [7] 9] However, these studies used different population groups. Also, previous studies examining health expenditure in IBD did not include all demographic factors. Because identification of these factors is important for policymakers and payers to establish the high-spending group, it was necessary to examine a more comprehensive list of factors that are associated with high expenditure among patients with IBD.
Due to the debilitating symptoms, patients with IBD are required to make scheduled specialist visits, be adherent to their medications and get continuous monitoring. [2] [3] [4] At some point, some patients with IBD would eventually have to use emergency rooms (ER) and hospitals. [10] However, some hospitalizations and ER visits can be prevented. [11, 12] Previous studies showed an increasing trend of the unnecessary, preventable utilization of inpatient care. [10, 11] With these unnecessary visits, inpatient services would be overloaded, leading to a decrease in the quality of care and an increase in health expenditure. Therefore, it is imperative to have appropriate diagnosis, monitoring and treatments in outpatient setting in treating IBD. [2] [3] [4] 10] One of the important factors that influences outpatient care is cost. Because IBD treatment is expensive, patients with insurance often have to pay a high out-of-pocket cost. [8] Thus, cost sharing, defined as the total copay and/or deductible, is an important factor that affects patients' decision to seek outpatient care. [13, 14] While high cost sharing would discourage patients from utilizing unnecessary care, it also can be a barrier of access to care for those who have chronic conditions (i.e. IBD), low incomes or both. [13, 14] Multiple studies have looked at the effect of high cost sharing from high deductible health plans on utilization and expenditure of outpatient and inpatient visits, the results were mixed. [15] [16] [17] [18] Overall, most of these studies had a macroscopic examination by including all conditions. There has been a gap in studying the impact of high cost sharing for a certain chronic condition or a group of closely related diseases.
IBD has shown to be costly. As the rate of emergency visits and hospitalization with IBD has been increasing, [11, 12] the costs of IBD has become a bigger burden. Adequate outpatient care is one solution. [19] [20] [21] [22] However, high cost sharing can be a barrier to obtain appropriate outpatient care. Appropriate outpatient care includes not only outpatient visits, but also medication use. Prior research has shown the positive correlation between high prescription cost sharing and medication nonadherence. [23] [24] [25] [26] [27] [28] Thus, there is a need to study the impact of cost sharing on outpatient utilization and medication adherence among patients with IBD. Additionally, there is a need to examine a more comprehensive list of cost-driving factors in IBD to identify high-spending patients for future cost containment strategy.
Methods
In this retrospective longitudinal study, we pooled data from the 1999-2013 Medical Expenditure Panel Survey (MEPS). [29] The study used data starting from 1999 because it was the first year after tumour necrosis factor antagonist, the newest drug class during this period, received approval for CD by the Federal Drug Agency. [30] MEPS is a nationally representative survey of the noninstitutionalized civilian population that is sponsored jointly by the Agency for Healthcare Research and Quality (AHRQ) and National Center for Health Statistics (NCHS). [29] MEPS provides nationally representative annual estimates of demographics, health service uses and frequency, health expenditure, payments, insurance, quality of life, medical conditions and prescribed medications through three major survey components -Household Component, Medical Provider Component and Insurance Component. [29] MEPS began surveying people in 1996. MEPS uses a rotating panel design to survey individuals in which data are collected from a group of participating individuals (about 35 000 individuals per year) in five rounds of interviews over 30 months. A new panel is started each subsequent year after the previous panel completes the survey duration.
Individuals were included in the study if they were over 18 years of age, had a diagnosis of IBD and had some type of insurance. To identify a person with IBD, an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code of 555 and 556 was used. [31] These files, with the exclusion of prescribed medicine files, contain information on demographic variables, geographic variables, health insurance status, outpatient visits, hospital visits, ER visits and expenditures associated with the use of health services. The prescribed medicines files include information regarding when the medication was purchased, dosage form, days' supply, expenditure and number of refills for each prescription. The information in these files includes drug names, imputed National Drug Codes, payment sources, drug categories and drug subcategories. ICD-9 codes of 555 and 556 were used to identify drugs used in IBD. The number of days' supply for IBD was obtained for each patient. The Medication possession ratio (MPR) was calculated for each patient by dividing total days of supply by total number of days evaluated. [32] Prior to 2010, MEPS did not provide information on the medication supply days. In order to estimate it, the study used available supply days to form a scheme that approximated the distribution of supply days for the data files of previous years. [33] This study broke down the number of dispensed quantity into different levels of approximated days of supply (i.e. omeprazole dispensed quantity of 30 meant 30 days of supply, or dispensed quantity of ≥60 and <90 meant 60 supplied days).
The outcome variables included annual health expenditure (outpatient, inpatient and prescription charges), annual number of IBD-related outpatient visits (hospital outpatient and office-based visits) and MPR. Each was categorized as either low or high level using the median as the cutoff point.
The independent variable included age, gender, race, ethnicity, BMI, education, insurance type, income, region, smoking, short-form 12 scores for quality of life (SF-12) and Charlson comorbidity index (CCI) score. This value is based on 19 comorbid conditions, each of which has a correlated prognostic weight ranging from 1 to 6. This index is a widely used validated method for estimating risk of death due to various comorbid conditions. It has also been validated for several other health outcomes besides death. [34] Only age, SF-12 scores and CCI were kept as continuous variable, while the rest were examined as categorical variables. Cost sharing was calculated for outpatient visit and prescription separately by dividing the total out-of-pocket costs by the total expenditure of each event or product. Cost sharing was then categorized as low or high level using the median as the cutoff point.
Due to the time horizon of 14 years, the study adjusted for inflation using the Personal Healthcare Index constructed by Centers of Medicare and Medicaid Services. [35] Logistic regression models were built to test the hypotheses. The complex survey design of MEPS was incorporated by using person-level weights for stratum, cluster and individual persons to obtain unbiased national estimates. All statistical analyses were performed using SAS 9.3 (SAS Institute Inc, Cary, NC, USA). A P value of <0.05 was considered to be statistically significant.
Results
A total of 391 patients met the study criteria and were included in the data analysis. At the beginning, there were 223 530 respondents in 14 longitudinal panels (years 1999-2013). Among these, only 447 respondents were identified to have diagnosis of IBD. Among these, about 56 patients were uninsured and were excluded from the study sample. The final study population included 391 patients with IBD and having either public or private health insurance.
The baseline characteristics of the studied population are summarized in Table 1 . The assigning weights of 391 patients represented a cohort of 9 499 909 patients who had IBD and health insurance. The sample had a fairly equal distribution of males and females (42.4% versus 57.8% respectively. The average of SF-12 score reported for quality of life was 42. Based on the diagnoses, the average CCI score was 0.85. The average outpatient and prescription cost sharing were 16% and 31% respectively. When ICD-9 code of 555 and 556 to select medications used in IBD, MEPS did not only provide medications used to treat IBD (i.e., mesalamine), but it also included medications for conditions related to IBD such as malnutrition or pain. That could partly explain the high prescription cost sharing (31%). The annual average of outpatient visit was about 3 (2.8). The average MPR was about 0.88 and the average annual health expenditure was $14 357.
Factors affecting health expenditure
The median of annual health expenditure was $6660, whic was used as the cutoff point to categorize expenditure as either high or low. Table 2 shows the significant cost-driving factors for high level of health expenditure in IBD.
Age, BMI, education, income level, quality of life (SF-12 score), CCI and region were identified as significant cost-driving factors. As age increased, it was less likely to belong to the high-expenditure group (OR 0.978; 95% CI, 0.961-0.995). Compared to overweight, underweight did not significantly associate with high expenditure, but normal weight was 1.6 times more likely to have high expenditure (OR 1.6; 95% CI, 1.065-2.43). There was no significant difference in the odd of having high expenditure between patients who graduated from high school and those with some college degree. However, patients who did not graduate from high school were 2.67 times more likely to have high expenditure (OR 2.67; 95% CI, 1.33-5.36). Also, patients who had low income (<$23 000 per year) were 48% less likely to have high expenditure compared to people earning more than $23 000 annually (OR 0.516; 95% CI, 0.268-0.994). Higher SF-12 scores (indicating better quality of life) associated significantly with the high level of expenditure (OR 1.025; 95% CI, 1.003-1.047). Interestingly, having higher CCI score were 25% less likely to have 
Effect of medical cost sharing on outpatient utilization
The median of IBD-related outpatient visits was 1 visit per year, which was used as the cutoff to categorize either low or high level of outpatient visits. Meanwhile, the median cost-sharing proportion for outpatient visits was 0.087, which was also used as the cutoff point for either low or high level of cost sharing. Table 3 shows the logistic regression results for high level of outpatient utilization. Race, ethnicity, BMI and cost sharing were significantly associated with more outpatient resource uses. Both black and other races were 2.5 and two times more likely to seek outpatient care for IBD than Caucasian (OR 2.5; 95% CI, 1.44-4.43 and OR 2.0; 1.43-3.23 respectively). Interestingly, Hispanics were also more likely to seek outpatient care for IBD than non-Hispanics by 4.5 times (OR 4.5; 95% CI, 2.35-8.66). There was no difference between normal and overweight patients, but underweight patients were 56% less likely to use outpatient care compared to overweight patients (OR 0.434; 95% CI, 0.23-0.809). Compared to high outpatient cost sharing, patients with low cost sharing were about three times more likely to make outpatient visits than patients with high cost sharing (OR 3.26; 95% CI, 1.87-5.7).
Effect of prescription cost sharing on medication adherence among inflammatory bowel disease patients
Using ICD-9 code of 555 and 556, drugs used in IBD were identified. However, medications used for IBD-related There were no differences in medication adherence among most baseline characteristics. Only ethnicity and smoking status were significantly associated with better medication adherence. Hispanics were 3.6 times more likely than non-Hispanics to be more adherent to IBD-related medications (OR 3.6; 95% CI, 1.82-7.35). Surprisingly, nonsmokers were 0.48 times or 52% less likely to have high level of medication adherence for IBD-related prescriptions (OR 0.52; 95% CI, 0.29-0.79). In this analysis, there was no difference in medication adherence between patients with low level of cost sharing and those with high level (OR 0.68; 95% CI, 0.43-1.1).
Due to the time horizon of 14 years, this study also looked at the effect of cost sharing among patients with IBD who were older than 65 years after Medicare Part D was implemented in 2005. Since 2005, there were 45 subjects who were identified as elderly (≥65 years old) and had IBD. Compared to high level of cost sharing, older patients with low levels of cost sharing were three times more likely to be adherent to those with high cost sharing (OR 3.143; 95% CI, 2.5-3.9). The sample size of patients who were 65 years or older before 2005 was not sufficient for an analysis.
Discussion
Age, BMI, education, income level, quality of life, CCI and region of residence were identified as significant cost-driving factors among patients with IBD. Lower the age with IBD, the expenditure for these conditions was more likely to increase. One possible explanation was due to the natural course of IBD. Majority of diagnoses of CD and UC occur before the age of 40.
[4] While IBD is expensive in general, stabilizing the diseases' flaring can be even more costly than remission maintenance, leading to higher expenditure in patients <65 years old. Additionally, the finding of effect of age on the health expenditure is in line with Prenzler et al., [9] while Kappelman et al. and Gunnarson et al. reported different results. [5, 6] This might have been because Prezler et al. included BMI and disease severity, while Kappelman et al. and Gunnarson et al. did not. In term of weight, normal weight was more likely to have higher expenditure than overweight. This finding contradicts with the results of Prezler et al. in which higher BMI had higher spending. However, BMI can be misleading because some people can still have high BMI if they have high muscle composition. Numerous sources have found that BMI might not be the best assessment of overweight or obesity. [36, 37] Some have recommended waist circumference measurement. [36] More investigation is needed to explore the relationship between person's weight and IBD-related expenditure. In term of education, patients who did not graduate from high school also were 2.7 times more likely to have higher costs compared to those who graduated from high school or had higher degrees. In term of income level, people with lower income were less like to spend for the diseases, which was logical due to their financial limitation and costs of IBD. In term of SF-12 score, patients with higher quality of life were more like to have high expenditure. For those with IBD, more spending can result in better control of the diseases leading to better quality of life. Interestingly, low CCI was less likely to incur high expenditure. Since younger age was associated with high expenditure, and young patients tended to have lower CCI scores, it might explain why low CCI was associated with low expenditure. In term of geographic areas, patients residing in the South were significantly more likely to incur more cost than those in the Northeast region. The Cost sharing and resource utilization Duy Vu Le et al.
finding was similar to that of Gunnarson et al. even though the result in Gunnarson et al. [6] was not significant. This could be due to variation in pricing and different rate of utilization among the region. In this analysis, patients from the Northeast region were less likely to make outpatient visits and be adherent to medication than the South. Even though these findings were not significant, but the trends might have reflected in significantly lower health expenditure of the Northeast when compared to the South.
In this sample, both black and other races were more likely to make IBD-related outpatient visits. Hispanics with IBD were also more likely to make more outpatient visits than non-Hispanics. These racial and ethnic differences could be due to cultural differences. Only small percentages of patients with IBD were from these minority groups (3.9% black, 20% others and 4.4% Hispanics). Since IBD is not common among minorities and has debilitating symptoms, these patients might be more likely to seek outpatient care than Caucasian patients. These results should not discard the possibility of ethnic and racial disparity in IBD, since this population only included those with some type of insurance. Underweight patients were less likely to visit outpatient clinic. Without proper care, patients with IBD, in turn, would have a high risk of being malnourished due to GI problems. [2] [3] [4] Finally, patients with lower outpatient cost sharing were more likely make more IBD-related outpatient visits than those with high outpatient cost sharing. This finding shows that out-of-pocket payment played a significant role in patients' tendency in outpatient utilization.
The study did not find significant association between demographic factors and medications, except ethnicity and smoking status. In term of ethnicity, Hispanics were more likely to be adherent than non-Hispanics, which again could be due to cultural differences. In term of smoking status, smokers were more likely to be adherent than nonsmokers. Previous studies have reported overuse of pain medications among smokers. [38] In this sample, pain medications were included in the final analysis, and about 8% of the sample reported 'refuse/don't know' for smoking. These factors could have altered the true effect of smoking on medication adherence. In terms of cost sharing, the analysis did not show a significant correlation between different levels of cost sharing and medication adherence. Previous studies have identified younger age, female, college degrees, costs and side effects as significant factors of medication nonadherence. [39] [40] [41] [42] Our result might have been due to the study's relative small sample size. Additionally, all medications used to calculate MPR included pain medications, antidepressants and other types of medications, beside medications used for IBD. In contrast, previous studies that examined medication adherence in IBD only focused a certain drug class or were conducted on a smaller geographic scales. [39] [40] [41] [42] However, for Medicare beneficiaries who had IBD since 2005, low cost sharing was associated with a higher medication adherence.
Our study suggests that to identify the high-spending group, policymakers and insurers may use age, education, income level and region of residency. Patients having IBD with younger age, low education, low income and residents of the South were more likely to have high expenditure. Payers should then promote cost-saving strategies (i.e. additional educational programs) with these high-spending patients. Even though there would be extra costs in short term, it would also promote better self-care, reduce inpatient visits and decrease overall costs in the long term. The results also indicate high cost sharing might be a barrier to optimal outpatient care leading to unnecessary inpatient visits. In order to cut long-term costs and to improve access to care, both availability of insurance coverage and low out-ofpocket are required.
Limitations
One limitation of the study was the follow-up period, which was limited in only 2 years due to MEPS' panel design. IBD is chronic, so 2 years might not be long enough to see true impacts. Also, data collected in MEPS were survey based. Accuracy problems were possible during both collection and data entry processes. Due to the low prevalence of IBD (~1.2 million nationwide), the study used a 14-year time horizon. Multiple changes have occurred during these 14 years such as policy change and introduction of new medication. To limit the error, the study purposely chose to examine 1999-2013 because 1999 was the first year after TNF-alpha, a newest drug class, was approved by FDA for CD. Another limitation of this study was the lack of severity data because IBD is treated by on clinical severity. Unfortunately, there has been a limited number of expenditure databases that provides both expenditure and clinical severity of these conditions in the USA. To compensate for lack of severity data, this study used quality of life and CCI as measurements to gauge subjects' well-being.
Conclusion
IBD is an expensive disease, so it requires adequate outpatient care to avoid unnecessary inpatient visits and low quality of life. Out-of-pocket costs have shown to be a significant factor that influences patients' care-seeking pattern in the outpatient setting. High cost sharing for patients can have negative impact on their outpatient care, which can increase inpatient visits and expenditure in long term. Using age, education, income and region of residence, policymakers and insurers can identify patients at risk of having high expenditure. Future research on developing different strategies such as having better access to outpatient clinics, medications for IBD and educational programmes may reduce inpatient visits and, thus, long-term costs.
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